Scrip
Amgen's Vectibix meets goal in pivotal first-line trial in colorectal cancer
07 August 2009
Malini Guha
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), has met its primary progression-free survival (PFS) endpoint in its pivotal Phase III trial, PRIME, in patients with newly diagnosed metastatic colorectal cancer (mCRC) who have a wild-type KRAS gene.
Detailed efficacy and...
Please Login to read the full article.
07 August 2009
Malini Guha
Detailed efficacy and...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vectibix clears PFS but survival hurdle still awaits in colorectal cancer
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- New analysis seeks to find mutations that predict response to Amgen's Vectibix in colorectal cancer
- Experts optimistic about Pfizer's crizotinib to treat subset of lung cancer
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
